Poor Results Prompt Takeda and Zinfandel to End Phase 3 Alzheimer’s Therapy Trial Early

Poor Results Prompt Takeda and Zinfandel to End Phase 3 Alzheimer’s Therapy Trial Early
Takeda Pharmaceutical Company and Zinfandel Pharmaceuticals have brought an early end to a Phase 3 clinical trial after their Alzheimer's therapy pioglitazone failed to prevent the development of mild cognitive impairment. The decision came less than a year after the partners completed enrollment in the TOMMORROW trial (NCT01931566). An interim analysis of the study's results showed that pioglitazone was unable to prevent people with normal cognition from developing the impairment seen in
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *